$CE

Celanese Corp (CE): Results of Operations and Financial Condition

Celanese Corp (CE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 q220268-kex992.htm EX-99.2 Document Exhibit 99.2 Non-U.S. GAAP Financial Measures and Supplemental Information August 4, 2026 In this document, the terms the "Company," "we" and "our" refer to Celanese Corporation and its subsidiaries on a consolidated basis. Purpose Th

Original reporting
Published Aug 4, 2026, 8:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CE
Neutral
medium confidence
Mentioned
$CE
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CENeutralLow
01

Why it matters

Because the provided content focuses on definitions and presentation rules, it is unlikely to change valuation assumptions by itself. Any trading impact would depend on whether the omitted portions contain new financial results or material changes.

02

Market read

Supplemental non-GAAP framework update for results and financial condition, with no explicit new numeric datapoints in the provided excerpt.

03

What to watch

If Exhibit 99.2 includes updated reconciliations or segment figures not shown in the scrape, the relevance could rise; the current text appears to be mostly methodology boilerplate.

Relevance 7/10Novelty 2/10Timing: filed Aug 4, 2026 (after market hours)

Background

The SEC 8-K Item 2.02 is accompanied by Exhibit 99.2 describing Celanese’s non-GAAP financial measures and how they reconcile to GAAP.

Company-level read

Ticker impact

$CENeutralMedium confidence
Context

Celanese filed an 8-K with Item 2.02 and an Exhibit 99.2 detailing its non-GAAP metrics framework for results and financial condition.

Expected impact

Limited near-term impact unless the missing tables include new financial datapoints beyond the non-GAAP definitions.

Evidence & confidence

The excerpt is dominated by definitions, purpose, and reconciliation methodology for adjusted EBIT, operating EBITDA, net debt, and free cash flow, without any new numeric results or forward-looking guidance.

Market effects

Minimal, as the excerpt does not introduce new segment performance, demand signals, or guidance.

None indicated.

None indicated.

Counterpoint

Traders may still use the updated non-GAAP definitions to interpret upcoming earnings comparisons, but the excerpt itself provides no new performance numbers.

Key entities

  • Celanese Corporation

    Subject issuer filing an 8-K (Item 2.02) with supplemental non-GAAP financial measures documentation.

Related articles

$CEMed

Celanese Corporation: Amsterdam District Court Rules in Favor of Celanese and its Co-Defendants in Shell and Repsol Cases, Dismissing All Claims

Celanese (NYSE: CE) said the Amsterdam District Court dismissed Shell Chemicals Europe’s damages claim and a Repsol entities claim seeking declaratory judgment of liability against Celanese and co-defendants. The cases stem from follow-on litigation related to a 2020 European Commission settlement over past ethylene purchases in North-Western Europe.

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.

$IXMed

Orix Corp Ads Q1 Earnings Call Highlights

ORIX (NYSE: IX) discussed Q1 results and outlook on an earnings call, including potential Q3 Kioxia sale and valuation losses tied to Kioxia’s end-September share price. ORIX shifted its dividend basis to adjusted profits, targeting an interim dividend of JPY 107.27 per share and full-year JPY 187.36. It reported JPY 115.7B capital gains and about JPY 300B capital-recycling inflows, and continued a JPY 250B buyback.

$CPTMedAI 8/10

Camden Property Trust (CPT) Q2 2026 Earnings Call Transcript

Camden Property Trust (CPT) discussed its Q2 2026 earnings call, focusing on exiting its California multifamily portfolio. According to management, it sold the 19-year-old California portfolio for $1.625 billion, with trailing 12-month FFO and AFFO yields of 5.6% and 5.2%. Camden repurchased $694 million of shares and closed $645 million of acquisitions plus $195 million of awarded acquisitions, reaffirming $6.75/share FFO guidance.